BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $NVO readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07184632-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:NNC0662-0419 readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine NN
 C0662-0419 Help People Living With Overweight or Obesity\n\nPrimary comple
 tion date: 2026-12-14 (estimated)\nPhase 2 · Cardio-Met · Overweight\, O
 besity\nEnrollment: 224 · Sites: 2\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07184632\nhttps://clinic
 altrials.gov/study/NCT07184632
URL:https://datacutoff.com/radar.html?nct=NCT07184632
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395687-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:UBT251 readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study on How Well Different Doses of the Medicine UB
 T251 Help People Living With Overweight or Obesity\n\nPrimary completion d
 ate: 2027-01-14 (estimated)\nPhase 2 · Cardio-Met · Overweight\, Obesity
 \nEnrollment: 333 · Sites: 3\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07395687\nhttps://clinicaltria
 ls.gov/study/NCT07395687
URL:https://datacutoff.com/radar.html?nct=NCT07395687
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076199-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:ONWARDS 11 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study to See How a Weekly Insulin\, Insulin Icodec\,
  Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine\, Bo
 th in Combination With Insulin Aspart\, in Adu…\n\nPrimary completion da
 te: 2027-01-25 (estimated)\nOriginally planned: 2026-11-23 (+2.1 months)\n
 Phase 3 · Cardio-Met · Diabetes Mellitus\, Type 1\nEnrollment: 877 · Si
 tes: 182\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT07076199\nhttps://clinicaltrials.gov/study/NCT07076
 199
URL:https://datacutoff.com/radar.html?nct=NCT07076199
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118281-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:ARTEMIS readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:ARTEMIS - A Research Study to Look at How Ziltivekimab Works Co
 mpared to Placebo in People With a Heart Attack\n\nPrimary completion date
 : 2027-01-29 (estimated)\nOriginally planned: 2026-09-03 (+4.9 months)\nPh
 ase 3 · Cardio-Met · Cardiovascular Risk\, Acute Myocardial Infarction (
 AMI)\nEnrollment: 10000 · Sites: 836\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06118281\nhttps://clin
 icaltrials.gov/study/NCT06118281
URL:https://datacutoff.com/radar.html?nct=NCT06118281
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011667-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:CagriSema (Cagrilintide B and Semaglutide I) readout (P3) · Novo N
 ordisk A/S $NVO
DESCRIPTION:A Research Study to Look at How Well CagriSema Helps People Liv
 ing With Obesity Lose Weight and Maintain Weight Loss in the Long-term\n\n
 Primary completion date: 2027-03-01 (estimated)\nOriginally planned: 2026-
 12-15 (+2.5 months)\nPhase 3 · Cardio-Met · Obesity\nEnrollment: 609 · 
 Sites: 47\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT07011667\nhttps://clinicaltrials.gov/study/NCT0701
 1667
URL:https://datacutoff.com/radar.html?nct=NCT07011667
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220642-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:RENEW 1 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:Weight Loss in People Living With Overweight or Obesity Followi
 ng Treatment With Cagrilintide\n\nPrimary completion date: 2027-05-11 (est
 imated)\nPhase 3 · Cardio-Met · Obesity\, Overweight\nEnrollment: 300 ·
  Sites: 40\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://datacuto
 ff.com/radar.html?nct=NCT07220642\nhttps://clinicaltrials.gov/study/NCT072
 20642
URL:https://datacutoff.com/radar.html?nct=NCT07220642
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:RENEW 2 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:Weight Loss in People Living With Overweight or Obesity and Typ
 e 2 Diabetes Following Treatment With Cagrilintide\n\nPrimary completion d
 ate: 2027-05-12 (estimated)\nPhase 3 · Cardio-Met · Overweight\, Obesity
 \, Type 2 Diabetes\nEnrollment: 330 · Sites: 67\n\nPrimary completion = l
 ast participant's primary-endpoint data collected\; topline results usuall
 y follow weeks to months later. Sponsor-reported\, often an estimate. Not 
 investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07220759\nh
 ttps://clinicaltrials.gov/study/NCT07220759
URL:https://datacutoff.com/radar.html?nct=NCT07220759
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979375-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270516
DTEND;VALUE=DATE:20270517
SUMMARY:8282-Reduced readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study Comparing CDR132L With Placebo on the Structur
 e and Function of the Heart in People With Heart Failure With Reduced/Mild
 ly Reduced Ejection Fraction and Left Vent…\n\nPrimary completion date: 
 2027-05-16 (estimated)\nPhase 2 · Cardio-Met · Heart Failure\nEnrollment
 : 200 · Sites: 92\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT06979375\nhttps://clinicaltrials.gov/stud
 y/NCT06979375
URL:https://datacutoff.com/radar.html?nct=NCT06979375
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745504-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:RENEW 4 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study to Compare Two Different Versions of Injectabl
 e Cagrilintide and Placebo in People With Excess Body Weight\n\nPrimary co
 mpletion date: 2027-05-18 (estimated)\nPhase 3 · Cardio-Met · Overweight
 \, Obesity\nEnrollment: 285 · Sites: 36\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07745504\nhttps://c
 linicaltrials.gov/study/NCT07745504
URL:https://datacutoff.com/radar.html?nct=NCT07745504
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817251-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CagriSema readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:Research Study on How People With Type 2 Diabetes Tolerate Swit
 ching From Semaglutide to Cagrisema\n\nPrimary completion date: 2027-06-09
  (estimated)\nPhase 3 · Cardio-Met · Diabetes Mellitus\, Type 2\nEnrollm
 ent: 210 · Sites: 40\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT07817251\nhttps://clinicaltrials.gov/s
 tudy/NCT07817251
URL:https://datacutoff.com/radar.html?nct=NCT07817251
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639021-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:NNC0662-0419 readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study Comparing Different Ways of Increasing the Dos
 e of NNC0662-0419 in Participants With Obesity\n\nPrimary completion date:
  2027-06-14 (estimated)\nPhase 2 · Cardio-Met · Obesity\nEnrollment: 233
  · Sites: 25\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://datac
 utoff.com/radar.html?nct=NCT07639021\nhttps://clinicaltrials.gov/study/NCT
 07639021
URL:https://datacutoff.com/radar.html?nct=NCT07639021
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612268-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Hibiscus 2 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:A Study to Evaluate How Well Etavopivat Works in People With Si
 ckle Cell Disease\n\nPrimary completion date: 2027-08-27 (estimated)\nOrig
 inally planned: 2025-12-15 (+20.4 months)\nPhase 3 · Rare · Sickle Cell 
 Disease\nEnrollment: 510 · Sites: 175\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06612268\nhttps://cli
 nicaltrials.gov/study/NCT06612268
URL:https://datacutoff.com/radar.html?nct=NCT06612268
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669755-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:REDEFINE 3 readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:REDEFINE 3: A Research Study to See the Effects of CagriSema in
  People Living With Diseases in the Heart and Blood Vessels\n\nPrimary com
 pletion date: 2027-09-01 (estimated)\nOriginally planned: 2027-05-05 (+3.9
  months)\nPhase 3 · Cardio-Met · Cardiovascular Disease\nEnrollment: 710
 1 · Sites: 633\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://dat
 acutoff.com/radar.html?nct=NCT05669755\nhttps://clinicaltrials.gov/study/N
 CT05669755
URL:https://datacutoff.com/radar.html?nct=NCT05669755
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415954-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:NNC0662-0419 readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study Comparing How Well Different Doses of the Medi
 cine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes\n\nPrim
 ary completion date: 2027-09-03 (estimated)\nPhase 2 · Cardio-Met · Diab
 etes Mellitus\, Type 2\nEnrollment: 270 · Sites: 63\n\nPrimary completion
  = last participant's primary-endpoint data collected\; topline results us
 ually follow weeks to months later. Sponsor-reported\, often an estimate. 
 Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0741595
 4\nhttps://clinicaltrials.gov/study/NCT07415954
URL:https://datacutoff.com/radar.html?nct=NCT07415954
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668388-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:UBT251 readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study Comparing How Well Different Doses of the Medi
 cine UBT251 Lower Blood Sugar in People With Type 2 Diabetes\n\nPrimary co
 mpletion date: 2027-10-04 (estimated)\nPhase 2 · Cardio-Met · Diabetes M
 ellitus\, Type 2\nEnrollment: 300 · Sites: 70\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07668388\nhtt
 ps://clinicaltrials.gov/study/NCT07668388
URL:https://datacutoff.com/radar.html?nct=NCT07668388
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811561-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271107
DTEND;VALUE=DATE:20271108
SUMMARY:FOCUS readout (P3) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study to Look at How Semaglutide Compared to Placebo
  Affects Diabetic Eye Disease in People With Type 2 Diabetes\n\nPrimary co
 mpletion date: 2027-11-07 (estimated)\nOriginally planned: 2025-02-05 (+33
 .0 months)\nPhase 3 · Cardio-Met · Diabetes Mellitus\, Type 2\nEnrollmen
 t: 1500 · Sites: 230\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT03811561\nhttps://clinicaltrials.gov/s
 tudy/NCT03811561
URL:https://datacutoff.com/radar.html?nct=NCT03811561
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979362-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:8212-Preserved readout (P2) · Novo Nordisk A/S $NVO
DESCRIPTION:A Research Study Comparing Different Doses of CDR132L With Plac
 ebo on the Structure and Function of the Heart in People With Heart Failur
 e With Preserved Ejection Fraction and Lef…\n\nPrimary completion date: 
 2027-11-16 (estimated)\nOriginally planned: 2027-05-16 (+6.0 months)\nPhas
 e 2 · Cardio-Met · Heart Failure\nEnrollment: 200 · Sites: 118\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT06979362\nhttps://clinicaltrials.gov/study/NCT06979362
URL:https://datacutoff.com/radar.html?nct=NCT06979362
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
